BGM Associates
  • What we do
    • Our services
    • Our Focus
  • Who we are
    • People
    • Advisory Board
  • Our Thinking
  • News
  • Careers
  • Contact us
  • What we do
    • Our services
    • Our Focus
  • Who we are
    • People
    • Advisory Board
  • Our Thinking
  • News
  • Careers
  • Contact us

NEWS

News about our organization and our activities​​

BGM supports US-Korean development and commercialization partnership for novel therapeutic approach in neurodegenerative diseases in South Korea

11/7/2017

 
Picture
​BGM Associates has assisted DuChemBio Co. Ltd. and Accera, Inc. to bring the proprietary medium chain triglyceride (MCT) technology to South Korea.

Accera, a leading CNS therapeutic company is focused on pioneering novel therapeutic approaches to treat neurodegenerative diseases caused by metabolic deficiencies, such as regional decreases in cerebral glucose metabolism associated with Alzheimer’s disease (see illustration). Accera’s proprietary MCT technology addresses this issue by providing the brain with ketone bodies, a natural alternative fuel to glucose.

DuChemBio has been active in the field of neurodegenerative diseases since 2012, primarily through commercializing nuclear medicine biomarkers for the diagnosis of Alzheimer’s and Parkinson’s diseases. BGM Associates is supporting DuChemBio in its endeavor to fully develop and commercialize Accera’s technology.

​Link to press release



Comments are closed.

    BGM News Blog

    We regularly publish news from within our firm and our focus industries

    News categories

    All
    Events
    Management & Personnel
    Projects
    Publications & Presentations

    View my profile on LinkedIn

CONNECT WITH US

info@bgmassociates.com
+49  30  8148  7127

VISIT OUR OFFICE

Winkler Straße 11
14193 Berlin – Germany

 

© COPYRIGHT 2012-2019. ALL RIGHTS RESERVED | ​TERMS OF USE | LEGAL NOTICE | PRIVACY POLICY